CN105102482A - 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途 - Google Patents

一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途 Download PDF

Info

Publication number
CN105102482A
CN105102482A CN201480017990.8A CN201480017990A CN105102482A CN 105102482 A CN105102482 A CN 105102482A CN 201480017990 A CN201480017990 A CN 201480017990A CN 105102482 A CN105102482 A CN 105102482A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480017990.8A
Other languages
English (en)
Other versions
CN105102482B (zh
Inventor
周清
冯晓
粘伟红
李玲云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOR BIOPHARMA CO Ltd
Original Assignee
GENOR BIOPHARMA CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOR BIOPHARMA CO Ltd filed Critical GENOR BIOPHARMA CO Ltd
Priority to CN201480017990.8A priority Critical patent/CN105102482B/zh
Priority to CN201811474561.XA priority patent/CN109517067B/zh
Publication of CN105102482A publication Critical patent/CN105102482A/zh
Application granted granted Critical
Publication of CN105102482B publication Critical patent/CN105102482B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供一种抗人RANKL抗体，其人源化抗体和它们的药物组合物和用途，所述抗人RANKL抗体可特异性结合如SEQIDNO:1所述的氨基酸序列，并且其重链包括SEQIDNO:2-9的氨基酸序列中之一所示的可变区，轻链包括SEQIDNO:10-17的氨基酸序列中之一所示的可变区。所述人源化抗体可特异性地与人RANKL结合，并且其重链可变区选自SEQIDNO:6、23、25、27或29所示的氨基酸序列，轻链可变区选自SEQIDNO:14、31、33、35、37或39所示的氨基酸序列。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201480017990.8A 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途 Active CN105102482B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201480017990.8A CN105102482B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途
CN201811474561.XA CN109517067B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013107539723 2013-12-31
CN201310753972.3A CN103965357B (zh) 2013-12-31 2013-12-31 一种抗人rankl抗体
CN201480017990.8A CN105102482B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途
PCT/CN2014/095236 WO2015101241A1 (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811474561.XA Division CN109517067B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途

Publications (2)

Publication Number Publication Date
CN105102482A true CN105102482A (zh) 2015-11-25
CN105102482B CN105102482B (zh) 2019-02-01

Family

ID=51235400

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201310753972.3A Active CN103965357B (zh) 2013-12-31 2013-12-31 一种抗人rankl抗体
CN201811474561.XA Active CN109517067B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途
CN201480017990.8A Active CN105102482B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途
CN201510901094.4A Active CN105732812B (zh) 2013-12-31 2015-12-08 一种抗人rankl人源化抗体及其药物组合物和用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201310753972.3A Active CN103965357B (zh) 2013-12-31 2013-12-31 一种抗人rankl抗体
CN201811474561.XA Active CN109517067B (zh) 2013-12-31 2014-12-28 一种抗人rankl抗体、其人源化抗体及它们的药物组合物和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510901094.4A Active CN105732812B (zh) 2013-12-31 2015-12-08 一种抗人rankl人源化抗体及其药物组合物和用途

Country Status (5)

Country Link
US (1) US9896510B2 (zh)
EP (1) EP3091030B1 (zh)
CN (4) CN103965357B (zh)
ES (1) ES2824101T3 (zh)
WO (1) WO2015101241A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111808198A (zh) * 2020-07-27 2020-10-23 佛山安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
CN117285637A (zh) * 2023-11-22 2023-12-26 江苏迈威康新药研发有限公司 一种抗独特型抗体及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
JP6766060B2 (ja) * 2014-11-14 2020-10-07 プロビオコン・ゲーエムベーハー 転移性疾患を処置するためのｒａｎｋｌ特異的薬剤
EP3085709B1 (en) * 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
CA3013443C (en) * 2016-02-01 2021-06-15 Eli Lilly And Company Parathyroid hormone - anti-rankl antibody fusion compounds
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
CN108753920A (zh) * 2018-06-21 2018-11-06 佛山安普泽生物医药股份有限公司 一种检测rankl靶向治疗药物生物学活性的方法
CN110878319A (zh) * 2018-09-06 2020-03-13 上海张江生物技术有限公司 一种tnf相关激活诱导细胞因子的制备方法
CN109504682A (zh) * 2018-11-09 2019-03-22 佛山安普泽生物医药股份有限公司 一种dna分子、慢病毒载体、细胞株及其应用
CN114555121A (zh) * 2019-08-29 2022-05-27 金德雷德生物科学股份有限公司 兽用抗il31抗体
KR20220119133A (ko) * 2019-12-27 2022-08-26 치오메 바이오사이언스 가부시키가이샤 항 cdcp1 항체
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
CN114099672B (zh) * 2022-01-28 2022-05-06 嘉和生物药业有限公司 具有增强稳定性的抗rankl人源化单克隆抗体的药物组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101514232A (zh) * 2009-03-25 2009-08-26 上海富莼科芯生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
CN101796072A (zh) * 2007-05-24 2010-08-04 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
CN101845098A (zh) * 2009-03-26 2010-09-29 中国人民解放军总医院 鼠rank/rankl胞外复合体的晶体,制备其的方法及其应用
CN102241776A (zh) * 2010-05-25 2011-11-16 首都医科大学 Rankl-tnf样区融合蛋白及其制备方法和应用
CN102741286A (zh) * 2010-03-26 2012-10-17 刘庆法 以pae技术开发的抗人rankl单抗及其应用
CN103060274A (zh) * 2012-12-28 2013-04-24 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US7364736B2 (en) * 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
US20140030276A1 (en) * 2011-03-31 2014-01-30 Oriental Yeast Co., Ltd. Cancer immunopotentiating agent containing rankl antagonist
CA2835340A1 (en) * 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796072A (zh) * 2007-05-24 2010-08-04 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
CN101514232A (zh) * 2009-03-25 2009-08-26 上海富莼科芯生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
CN101845098A (zh) * 2009-03-26 2010-09-29 中国人民解放军总医院 鼠rank/rankl胞外复合体的晶体,制备其的方法及其应用
CN102741286A (zh) * 2010-03-26 2012-10-17 刘庆法 以pae技术开发的抗人rankl单抗及其应用
CN102241776A (zh) * 2010-05-25 2011-11-16 首都医科大学 Rankl-tnf样区融合蛋白及其制备方法和应用
CN103060274A (zh) * 2012-12-28 2013-04-24 首都医科大学 Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIRK M. A等: "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", 《NATURE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111808198A (zh) * 2020-07-27 2020-10-23 佛山安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
CN111808198B (zh) * 2020-07-27 2022-06-03 广东安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
CN117285637A (zh) * 2023-11-22 2023-12-26 江苏迈威康新药研发有限公司 一种抗独特型抗体及其应用
CN117285637B (zh) * 2023-11-22 2024-03-22 江苏迈威康新药研发有限公司 一种抗独特型抗体及其应用

Also Published As

Publication number Publication date
CN105732812B (zh) 2019-03-08
US20160333101A1 (en) 2016-11-17
CN105102482B (zh) 2019-02-01
EP3091030A1 (en) 2016-11-09
CN103965357A (zh) 2014-08-06
CN105732812A (zh) 2016-07-06
CN109517067A (zh) 2019-03-26
EP3091030A4 (en) 2017-11-29
CN109517067B (zh) 2021-12-03
ES2824101T3 (es) 2021-05-11
WO2015101241A1 (zh) 2015-07-09
EP3091030B1 (en) 2020-07-15
CN103965357B (zh) 2016-08-17
US9896510B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
CN105732812B (zh) 一种抗人rankl人源化抗体及其药物组合物和用途
US11858981B2 (en) Humanization of rabbit antibodies using a universal antibody framework
ES2943577T3 (es) Direccionamiento doble
KR101947520B1 (ko) 안정한 가용성 항체
KR20150131360A (ko) ＴＮＦα에 대해 지시된 이원 특이적 결합 단백질
CN102958537A (zh) TNF-α结合蛋白
CN115109156B (zh) 一种靶向bcma的纳米抗体及其应用
CN108148136A (zh) 抗vegf抗体
EP3085709B1 (en) Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
JP2022542088A (ja) 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
JP6903083B2 (ja) 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant